Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Not applicable Interventional

Treatment of Adenocarcinoma of the Rectum With Transanal Local Excision for Complete Responders

ClinicalTrials.gov ID: NCT03941366

Public ClinicalTrials.gov record NCT03941366. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Treatment of T2-T3/NO-N+ Adenocarcinoma of the Rectum by Neoadjuvant Chemotherapy (FOLFOX) Followed by Preoperative Chemo (5FU/Capecitabine)-Radio Therapy (CRT) With Transanal Local Excision for Complete Responders

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The current standard of care for rectal cancer has diminished local recurrence and enhanced survival. Quality of life, however, remains poor for many patients and the probability of distant recurrence is high. In this study, we will attempt to reduce the distant recurrence rate and improve quality of life by making changes in the timing and administration of chemotherapy and radiation and doing less invasive rectal surgery when indicated.

Study identification

NCT ID
NCT03941366
Recruitment status
Terminated
Study type
Interventional
Phase
Not applicable
Lead sponsor
Henry Ford Health System
Other
Enrollment
15 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 95 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 25, 2016
Primary completion
Feb 28, 2023
Completion
Mar 31, 2025
Last update posted
Jul 22, 2026

2016 – 2025

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Ascension St. John Hospital Detroit Michigan 48236

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03941366, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 22, 2026 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03941366 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →